23 results
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
10 May 24
Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates
8:45am
not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab. Checkpoint intends to seek
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
22 Mar 24
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
8:52am
in the clinical data and safety package in support of cosibelimab. We look forward to providing additional updates in the second quarter.”
2023 and Recent … about the clinical data package, safety, or labeling for the approvability of cosibelimab. Checkpoint intends to address the feedback in a BLA
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
18 Dec 23
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
7:10am
Manufacturer
FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab
Waltham, MA … in a resubmission.
The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab.
“As the only
8-K
EX-1.1
x1c12 cd9cv9zlcu4vuh
21 Sep 20
Entry into a Material Definitive Agreement
5:26pm
8-K
EX-1.1
fsnuwkgv9dqbv54dbtqo
20 Nov 19
Entry into a Material Definitive Agreement
4:50pm
10-12G/A
EX-10.19
4oais9cn9ri0x
19 Aug 16
Registration of securities (amended)
12:00am
10-12G
EX-10
gfyllg51x1d
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
8ojgi
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
2e22sfmroix162
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
o72p5fipf
11 Jul 16
Registration of securities
12:00am
10-12G
EX-10
l1k9uj
11 Jul 16
Registration of securities
12:00am
10-12G/A
EX-10
yfnc8fkf248nv 9pvuw
16 May 16
Registration of securities (amended)
12:00am